Efficacy of an evidence-based telehealth-delivered weight-loss intervention to expand reach and enhance access to underserved groups after stroke

IF 1.4 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

Contemporary Clinical Trials Communications Pub Date : 2025-02-11 DOI:10.1016/j.conctc.2025.101458

Evan Elizabeth McShan , Shahad Alrawi , Stephanie Calhoun , Taylor Gilliland , Monica Bennett , Rosemary Dubiel , Simon Driver

{"title":"Efficacy of an evidence-based telehealth-delivered weight-loss intervention to expand reach and enhance access to underserved groups after stroke","authors":"Evan Elizabeth McShan , Shahad Alrawi , Stephanie Calhoun , Taylor Gilliland , Monica Bennett , Rosemary Dubiel , Simon Driver","doi":"10.1016/j.conctc.2025.101458","DOIUrl":null,"url":null,"abstract":"<div><div>Obesity is a risk factor for stroke, and survivors of stroke have a high rate of obesity and greater burden of obesity-related chronic conditions (e.g., heart disease, hypertension, re-occurring stroke) compared to the general population. Despite the health disparity, there is a lack of evidence-based weight-loss interventions tailored to individuals post stroke, as most health promotion programs exclude this population. Our team's work modifying and examining the efficacy of a modified version of the Diabetes Prevention Program Group Lifestyle Balance for people post stroke (GLB-CVA) is promising with results from an in-person randomized controlled trial (RCT) showing significant weight-loss (10.1 ± 16.8 lbs. [4.88 %]) and improvements in waist circumference, diastolic blood pressure, pain, social participation, eating practices, and health habits at 12-months post intervention. To expand the reach and accessibility of the GLB-CVA intervention, we will complete a RCT to assess the efficacy of telehealth delivery by enrolling 94 participants post stroke over a 3-year period. Results may provide an evidence-based, scalable telehealth weight-loss program designed for people post stroke that clinicians and community workers can use to increase accessibility to underserved groups.</div></div>","PeriodicalId":37937,"journal":{"name":"Contemporary Clinical Trials Communications","volume":"44 ","pages":"Article 101458"},"PeriodicalIF":1.4000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary Clinical Trials Communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2451865425000328","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Obesity is a risk factor for stroke, and survivors of stroke have a high rate of obesity and greater burden of obesity-related chronic conditions (e.g., heart disease, hypertension, re-occurring stroke) compared to the general population. Despite the health disparity, there is a lack of evidence-based weight-loss interventions tailored to individuals post stroke, as most health promotion programs exclude this population. Our team's work modifying and examining the efficacy of a modified version of the Diabetes Prevention Program Group Lifestyle Balance for people post stroke (GLB-CVA) is promising with results from an in-person randomized controlled trial (RCT) showing significant weight-loss (10.1 ± 16.8 lbs. [4.88 %]) and improvements in waist circumference, diastolic blood pressure, pain, social participation, eating practices, and health habits at 12-months post intervention. To expand the reach and accessibility of the GLB-CVA intervention, we will complete a RCT to assess the efficacy of telehealth delivery by enrolling 94 participants post stroke over a 3-year period. Results may provide an evidence-based, scalable telehealth weight-loss program designed for people post stroke that clinicians and community workers can use to increase accessibility to underserved groups.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Contemporary Clinical Trials Communications Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

2.70

自引率

6.70%

发文量

146

审稿时长

20 weeks

期刊介绍： Contemporary Clinical Trials Communications is an international peer reviewed open access journal that publishes articles pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from a wide range of disciplines including medicine, life science, pharmaceutical science, biostatistics, epidemiology, computer science, management science, behavioral science, and bioethics. Contemporary Clinical Trials Communications is unique in that it is outside the confines of disease specifications, and it strives to increase the transparency of medical research and reduce publication bias by publishing scientifically valid original research findings irrespective of their perceived importance, significance or impact. Both randomized and non-randomized trials are within the scope of the Journal. Some common topics include trial design rationale and methods, operational methodologies and challenges, and positive and negative trial results. In addition to original research, the Journal also welcomes other types of communications including, but are not limited to, methodology reviews, perspectives and discussions. Through timely dissemination of advances in clinical trials, the goal of Contemporary Clinical Trials Communications is to serve as a platform to enhance the communication and collaboration within the global clinical trials community that ultimately advances this field of research for the benefit of patients.